The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis.
Fiche publication
Date publication
février 2022
Journal
International journal of molecular sciences
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LAVALLE Philippe
Tous les auteurs :
Mancino D, Kharouf N, Scavello F, Hellé S, Salloum-Yared F, Mutschler A, Mathieu E, Lavalle P, Metz-Boutigue MH, Haïkel Y
Lien Pubmed
Résumé
Resistance to antifungal therapy of and non- strains, frequently associated with oral candidosis, is on the rise. In this context, host-defense peptides have emerged as new promising candidates to overcome antifungal resistance. Thus, the aim of this study was to assess the effectiveness against species of different Catestatin-derived peptides, as well as the combined effect with serum albumin. Among Catestatin-derived peptides, the most active against sensitive and resistant strains of . , and was the -isomer of Cateslytin (-bCtl) whereas the efficiency of the -isomer (-bCtl) significantly decreases against strains. Images obtained by transmission electron microscopy clearly demonstrated fungal membrane lysis and the leakage of the intracellular material induced by the -bCtl and -bCtl peptides. The possible synergistic effect of albumin on Catestatin-derived peptides activity was investigated too. Our finding showed that bovine serum albumin (BSA) when combined with the - isomer of Catestatin (-bCts) had a synergistic effect against especially at low concentrations of BSA; however, no synergistic effect was detected when BSA interacted with -bCtl, suggesting the importance of the C-terminal end of -bCts (GPGLQL) for the interaction with BSA. In this context in vitro -bCtl, as well as the combination of BSA with -bCts are potential candidates for the development of new antifungal drugs for the treatment of oral candidosis due to and non-, without detrimental side effects.
Mots clés
Catestatin, antifungal, antimicrobial peptides, candidosis, resistance
Référence
Int J Mol Sci. 2022 Feb 13;23(4):